Oral Alitretinoin for Severe Chronic Hand Eczema
For severe chronic hand eczema refractory to potent topical corticosteroids, initiate oral alitretinoin 30 mg once daily for 12-24 weeks, with mandatory pregnancy prevention in women of childbearing potential and monitoring of lipids, liver function, and thyroid function every 4 weeks.
Dosing Regimen
Start with alitretinoin 30 mg once daily, as this dose demonstrates superior efficacy compared to 10 mg 1. The 30 mg dose achieves response rates of approximately 43-63% (clear/almost clear hands) versus only 12.5% with 10 mg 2, 3. Treatment duration should be 12-24 weeks minimum 4, 5. Longer treatment duration at 30 mg correlates with better outcomes 1. If adverse effects are intolerable, dose reduction to 10 mg is permissible, though efficacy will be reduced 3.
Response typically begins at 4 weeks but most patients require 4-8 weeks, with some not improving until 14+ weeks 6. Do not discontinue prematurely—insufficient response is the most common reason for poor compliance, but 83% of initial non-responders eventually respond with continued treatment 7, 8.
Mandatory Monitoring
Baseline Requirements
- Pregnancy test (must be negative; repeat monthly during treatment and 1 month after)
- Lipid panel (triglycerides, cholesterol, HDL, LDL)
- Liver function tests
- Thyroid function tests
- Creatine phosphokinase
- Complete blood count
During Treatment
- Monthly lipid monitoring is essential—hyperlipidemia occurs in 20-40% of patients (primarily triglyceride elevation) 7, 9
- Monthly liver function tests
- Monthly pregnancy testing in women of childbearing potential
- Thyroid function every 2-3 months
Hyperlipidemia is dose-dependent and typically reverses within 4-8 weeks after discontinuation 7.
Absolute Contraindications
- Pregnancy or inadequate contraception in women of childbearing potential (alitretinoin is highly teratogenic, causing craniofacial dysmorphias, limb abnormalities, and CNS malformations) 7
- Hepatic impairment
- Severe renal impairment
- Uncontrolled hyperlipidemia
- Uncontrolled hypothyroidism
- Hypervitaminosis A
- Concurrent tetracycline/minocycline use (risk of benign intracranial hypertension) 7
Pregnancy Prevention Program (Women of Childbearing Potential)
Two forms of contraception must be used simultaneously, starting 1 month before treatment, throughout treatment, and for 1 month after discontinuation 7. This is non-negotiable. Monthly pregnancy testing is mandatory. Document contraceptive counseling and patient understanding in the medical record.
Patient Counseling Points
Expected Adverse Effects (occur in ~44-48% of patients) 9, 3:
- Headache (most common, ~29%)—usually mild-moderate, dose-dependent
- Dry skin, lips, eyes
- Skin fissures
- Nausea
- Back pain
- Elevated triglycerides (monitor closely)
Serious but Rare Adverse Effects:
- Benign intracranial hypertension: Severe headache, nausea, vomiting, visual disturbances—discontinue immediately and refer for neurological evaluation 7
- Depression (reported more frequently in post-marketing surveillance than trials) 9
- Inflammatory bowel disease (very rare) 9
Practical Instructions:
- Take with food to optimize absorption
- Avoid vitamin A supplements (risk of hypervitaminosis A)
- Use fragrance-free emollients liberally—continue topical skin care 10
- Avoid alcohol (hepatotoxicity risk, lipid effects)
- Report severe headaches, mood changes, or visual disturbances immediately
Clinical Pearls
Cost is a major barrier—34.7% of patients discontinue due to expense 8. Address this upfront with prior authorization support and patient assistance programs.
Hyperkeratotic hand eczema responds best to alitretinoin (51% reduction in one RCT) 7. Vesicular hand eczema may respond better to cyclosporine 11, though alitretinoin remains effective across all subtypes 4.
Relapse rates are low—only 15% of responders relapse at 16-week follow-up 6. However, retreatment is often necessary and appears safe based on post-marketing surveillance of ~250,000 patients 9.
No teratogenicity has been reported in humans from paternal exposure, but the theoretical risk exists 7.
When Alitretinoin Fails
If no response after 24 weeks at 30 mg, consider alternative systemic therapy (cyclosporine, methotrexate, dupilumab) or phototherapy 10, 12. Ensure compliance was adequate and consider patch testing to rule out allergic contact dermatitis as a contributing factor 10.